Blue Trust Inc. Buys 79 Shares of Bio-Rad Laboratories, Inc. $BIO

Blue Trust Inc. grew its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 5.5% in the second quarter, HoldingsChannel reports. The fund owned 1,517 shares of the medical research company’s stock after acquiring an additional 79 shares during the period. Blue Trust Inc.’s holdings in Bio-Rad Laboratories were worth $366,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the stock. Patriot Financial Group Insurance Agency LLC raised its stake in shares of Bio-Rad Laboratories by 25.9% in the second quarter. Patriot Financial Group Insurance Agency LLC now owns 1,441 shares of the medical research company’s stock worth $348,000 after acquiring an additional 296 shares during the last quarter. RK Asset Management LLC raised its position in shares of Bio-Rad Laboratories by 0.8% during the second quarter. RK Asset Management LLC now owns 14,502 shares of the medical research company’s stock worth $3,501,000 after acquiring an additional 113 shares during the last quarter. Public Employees Retirement System of Ohio raised its position in shares of Bio-Rad Laboratories by 3.6% during the second quarter. Public Employees Retirement System of Ohio now owns 6,307 shares of the medical research company’s stock worth $1,522,000 after acquiring an additional 218 shares during the last quarter. GAMMA Investing LLC raised its position in shares of Bio-Rad Laboratories by 20.9% during the second quarter. GAMMA Investing LLC now owns 734 shares of the medical research company’s stock worth $177,000 after acquiring an additional 127 shares during the last quarter. Finally, UMB Bank n.a. raised its position in shares of Bio-Rad Laboratories by 89.8% during the second quarter. UMB Bank n.a. now owns 167 shares of the medical research company’s stock worth $40,000 after acquiring an additional 79 shares during the last quarter. 65.24% of the stock is owned by institutional investors.

Bio-Rad Laboratories Stock Up 2.0%

Shares of NYSE:BIO opened at $303.56 on Tuesday. The firm has a market cap of $8.21 billion, a P/E ratio of 25.88 and a beta of 0.97. The company has a quick ratio of 3.67, a current ratio of 5.12 and a debt-to-equity ratio of 0.17. Bio-Rad Laboratories, Inc. has a 12-month low of $211.43 and a 12-month high of $387.99. The business has a fifty day simple moving average of $286.62 and a 200 day simple moving average of $256.93.

Bio-Rad Laboratories (NYSE:BIO) last issued its quarterly earnings data on Thursday, July 31st. The medical research company reported $2.61 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.93 by $0.68. Bio-Rad Laboratories had a return on equity of 4.01% and a net margin of 12.50%.The company had revenue of $651.60 million during the quarter, compared to the consensus estimate of $614.82 million. During the same period last year, the company earned $3.11 earnings per share. The firm’s revenue was up 2.1% compared to the same quarter last year. Bio-Rad Laboratories has set its FY 2025 guidance at EPS. Analysts predict that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current year.

Wall Street Analyst Weigh In

BIO has been the subject of several recent research reports. Royal Bank Of Canada boosted their price objective on Bio-Rad Laboratories from $387.00 to $409.00 and gave the stock an “outperform” rating in a report on Friday, August 1st. Wall Street Zen downgraded Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research report on Friday, August 22nd. Wells Fargo & Company increased their price objective on shares of Bio-Rad Laboratories from $245.00 to $265.00 and gave the company an “equal weight” rating in a research note on Friday, August 1st. Weiss Ratings reiterated a “sell (d)” rating on shares of Bio-Rad Laboratories in a research note on Saturday, September 27th. Finally, Zacks Research upgraded Bio-Rad Laboratories from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 26th. Three investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $333.50.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.